Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
521.00
0.00 (0.00%)
At close: Jun 27, 2025, 4:00 PM
524.00
+3.00 (0.58%)
After-hours: Jun 27, 2025, 7:50 PM EDT
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.03B in the quarter ending March 31, 2025, a decrease of -3.70%. This brings the company's revenue in the last twelve months to $14.09B, up 7.52% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.09B
Revenue Growth
+7.52%
P/S Ratio
3.92
Revenue / Employee
$932,457
Employees
15,106
Market Cap
55.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
REGN News
- 1 day ago - Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025 - GlobeNewsWire
- 3 days ago - Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade - Seeking Alpha
- 4 days ago - Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization - GlobeNewsWire
- 8 days ago - Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease - WSJ
- 8 days ago - Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid - GlobeNewsWire
- 8 days ago - Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) - GlobeNewsWire
- 11 days ago - Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer - Reuters
- 13 days ago - Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study - GlobeNewsWire